POST Online Media Lite Edition


Fosun: China to test BioNTech’s coronavirus vaccine

Christian Fernsby |
Shanghai Fosun Pharmaceutical announced that its subsidiary Shanghai Fosun Pharmaceutical Industrial Development has received the acceptance notice of clinical trial application for the licensed coronavirus vaccine product candidate BNT162b1.

Article continues below

Topics: FOSUN   

The clinical trial application of the Vaccine was accepted by the National Medical Products Administration (the “NMPA”).

In March 2020, Fosun Pharma has obtained the license granted by German company BioNTech to exclusively develop and commercialize its vaccine products based on BioNTech’s proprietary mRNA technology platform targeting coronavirus in China.

The Vaccine candidate is a prophylactic biological product, aiming at the precaution of coronavirus for people who aged 18 or above.

According to public information, BioNTech has announced interim analysis data from an ongoing phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2, and its two most advanced mRNA-based SARS-COV-2 vaccine candidates BNT162b1 and BNT162b2 have recently received the Fast Track Designation from the U.S. Food and Drug Administration (FDA). Subject to approval by regulatory authorities, BioNTech expects to begin a Phase 2b/3 trial as early as in later this month and expects up to 30,000 subjects to be enrolled in the trial.

What to read next

Fosun Pharma to invest $240 million in Alma Lasers
Fosun signs two European deals in one day
China's Fosun sells off Sydney tower